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The recent demonstration that immunotherapeutic approaches may be clinically eﬀective for cancer patients has renewed the
interest for this strategy of intervention. In particular, clinical trials using adoptive T-cell therapies disclosed encouraging results,
particularly in the context of Epstein-Barr-virus- (EBV-) related tumors. Nevertheless, the rate of complete clinical responses
is still limited, thus stimulating the development of more eﬀective therapeutic protocols. Considering the relevance of innate
immunity in controlling both infections and cancers, innovative immunotherapeutic approaches should take into account also
this compartment to improve clinical eﬃcacy. Evidence accumulated so far indicates that innate immunity eﬀectors, particularly
NK cells, can be exploited with therapeutic purposes and new targets have been recently identiﬁed. We herein review the complex
interactions between EBV and innate immunity and summarize the therapeutic strategies involving both adaptive and innate
immune system, in the light of a fruitful integration between these immunotherapeutic modalities for a better control of EBV-
driven tumors.
1.Introduction
An increasing number of clinical trials involving cell-based
immunotherapies is ongoing for the prevention and treat-
ment of diﬀerent types of human cancers [1–3]. These thera-
peutic approaches involve two diﬀerent modalities: active
cellular immunotherapies, that rely on autologous dendritic
cells or other antigen presenting cells [4, 5]a n da d o p t i v e
T-cell therapies (ACT), in which the ex vivo activation, ex-
pansion, and subsequent reinfusion of tumor-reactive T cells
hopefully result in attack and elimination of tumors [6–8].
Nevertheless, due to its complexity and costs ACT can be
performed only by a limited number of specialized centers
and it is still challenging to adapt this treatment for a broad-
er use. Perhaps one of the best studied ACT approaches is
constituted by the adoptive immunotherapy of EBV-associ-
ated malignancies.
The Epstein-Barr Virus (EBV) is a double-stranded DNA
virus, a member of the gamma herpes virus family and has
a genome comprising approximately 172kb pairs. Over 70
open reading frames allow for the transcription of genes
for a large number of diﬀerent viral proteins. Expression of
diﬀerent combinations of these proteins allows the virus to
establish diﬀerent forms of infection. Thus, in lytic infection,
the virus expresses the full complement of immediate early,
early,andlatelyticcycleproteinsandiscapableofreplicating
within the host cell. In latent infection, the virus expresses
a smaller number of proteins and does not replicate but is
able to persist within the host cell. Four latency types have
been described depending on which of these latent genes are2 Clinical and Developmental Immunology
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Figure 1: Interplay between EBV and innate immunity eﬀectors. Main activating (dark lines) and inhibitory (red lines) eﬀects of EBV
infection on B lymphocytes (B), neutrophils (N), macrophages (MA), monocytes (MO), epithelial (E), dendritic (DC), and natural killer
(NK) cells. Potential sites of intervention of targeted therapy approaches are also suggested (arrows). For further insights see text.
expressed, as shown in Figure 1. Long-lived EBV-carrying
memory B lymphocytes may express a putative Latency 0,
characterized by complete silencing of the viral genome, or a
Latency I, in which LMP-2A alone or together with EBNA-1
may be expressed [9]. The expression of these viral proteins
is crucial for establishing and maintaining EBV persistence
in memory B lymphocytes. An intermediate form of latency
(Latency II) has been identiﬁed in B-lymphocytes homing to
the germinal centers of lymphoid follicles [10]. In these cells,
the expression of EBV proteins is restricted to EBNA-1 and
the LMPs (LMP-1, -2A, and -2B), a “rescue” program that
provides signals allowing infected lymphoblasts to survive
and diﬀerentiate into memory B cells. In the absence of
eﬀective immune surveillance, as observed in vitro or in vivo
inimmunesuppressedpatients,EBV-infectedBlymphocytes
show a diﬀerent latency program, called Latency III, charac-
terized by the expression of the six EBV nuclear antigens
(EBNA1-6) and the three LMPs [11]. During latency, EBV
also expresses two small noncoding RNAs, known as EBER1
and EBER2 (167 and 172 nucleotides, resp.), the most
abundant RNAs in EBV-infected cells [12]. Furthermore, a
growing body of data indicates that viruses, including EBV,
exploit the cellular microRNA (miRNA) machinery to mod-
ulate and/or subvert virus-host cell interactions [13–15].
miRNAsare19-to25-nucleotide-longsingle-strandedRNAs
processed from transcripts with stem-loop structures [16]
and endowed with diverse functions, including the regula-
tion of cellular diﬀerentiation, proliferation, and apoptosis
[17–19]. miRNAs might also function as tumor suppressors
[20]o ro n c o g e n e s[ 20, 21].
Primary EBV infection mainly takes place in the oropha-
ryngeal region to which the virus is conveyed by saliva drop-
lets from infected individuals [22]. The nature of the target
cells in the oral mucosa is still controversial, but there is
agreement that B cells are infected at some stage of the
process. If infection is delayed to adolescence or adulthood,
it can cause infectious mononucleosis (IM), a self-resolving
lymphoid disorder largely resulting from an uncontrolled
T-cell reaction directed against EBV-infected cells. In IM
patients, EBV is exclusively found in B blasts that undergo
continuous proliferation under the inﬂuence of all latent
genes (Latency III). Following resolution of primary infec-
tion, EBV establishes a lifelong persistence in memory B cells
where the virus usually remains clinically silent. In this B-cellClinical and Developmental Immunology 3
reservoir, viral expression is entirely repressed, a process de-
scribed as a “True Latency”. The pleiotropic nature of EBV
target cells in vivo, including B and T lymphocytes, NK cells,
squamous and glandular epithelia, and smooth muscle cells,
demonstrates that the virus possesses the ability to infect a
large spectrum of diﬀerent cell types [23].
2.EBV-AssociatedDiseases
2.1. Infectious Mononucleosis. EBV is one of a variety of in-
fectious agents that can induce an infectious mononucleosis
syndrome. IM may be misdiagnosed as a high-grade large B-
celllymphoma,orevenHodgkin’slymphoma,particularlyin
cases containing a large number of B immunoblasts, some
of which express CD30, and rare Reed-Sternberg like cells
[24]. EBV-infected B-cells in IM show a typical Latency III
expression pattern including EBERs, EBNA1, EBNA2, and
LMP1, which renders virus detection very easy. However,
the mere presence of EBV does not exclude a large B cell
lymphoma, but detection of EBNA2 expression in infected
cells strongly suggests the diagnosis of IM.
2.2. EBV-Associated Tumors in Immunosuppressed Individ-
uals. The role of the immune system in controlling EBV
latent infection is best illustrated by the observation that
individuals with a congenital or acquired (e.g., after HIV
infection or organ transplantation) immune deﬁciency are
at increased risk to develop EBV-associated diseases, whose
histological type varies according to the type and the severity
of immunodeﬁciency. In these cases, the clinical context is
more suggestive for the diagnosis of this category of tumors
than the detection of EBV alone [25]. Accordingly, consider-
ing that the pattern of EBV latent gene expression may also
vary concomitantly with cytomorphological changes [26],
the assessment of viral status can have important consequen-
ces for the treatment of these lymphomas, as EBV-positive
lesions are in principle amenable to EBV-speciﬁc T-cell ther-
a p yo re v e nt oa n t i v i r a lt h e r a p y .
2.2.1. Posttransplant Lymphoproliferative Disorders. Post-
transplant lymphoproliferative disorder (PTLD) is thought
to result from iatrogenic immune suppression and chronic
antigenicstimulationfromtheengraftedorganafterhemato-
poieticstemcell(HSC)orsolidorgantransplantation(SOT).
PTLD includes a wide spectrum of diseases ranging from
polyclonalreactivelymphoidhyperplasiatomonoclonalma-
lignant lymphoma. About 80% of PTLDs are associated
with EBV and its overall incidence is about 1% in patients
with hematopoietic cell transplantation and less than 2%
in those with solid-organ transplantation. PTLD is more
common in pediatric patients, largely because children are
more likely to be primarily infected with EBV via the graft
and the risk of developing PTLD is greatest during the
ﬁrst year after transplantation and declines thereafter [27].
After hematopoietic cell transplantation, this disease may
involve nodal and extranodal sites, while PTLD after solid-
organ transplantation frequently involves the allograft itself,
which suggests a lymphomagenic role of chronic antigen
stimulation occurring within the graft [28]. Other sites are
also frequently involved, such as the gastrointestinal tract,
liver, lungs, lymph nodes, bone marrow, skin, and central
nervous system. Interestingly, PTLD occurring in the setting
of primary EBV infection or associated with use of the
immunosuppressive OKT3 antibody is often seen very early
after the transplant in heart, kidney, and pancreas allograft
recipients [29, 30]. Moreover, the reduction of pharmac-
ologic load of immunosuppressive drugs may also lower
the incidence of PTLD, by restoring EBV-speciﬁc immunity,
provided that the risk of acute rejection of the allograft is
closely monitored [31]. Finally, chemotherapy and anti-
B-cell antibodies may be used in combination with the
reduction in immune suppression, whereas surgery may be
considered for localized PTLDs. Reduction of immune sup-
pression alone results in clinical remission in 25–63% of
adult and in 40–86% of pediatric PTLD patients [27].
2.2.2. HIV-Associated Lymphomas. Patients with HIV infec-
tion are at 60 to 200-fold increased risk of developing
various lymphomas, considered as the ﬁrst acquired-immu-
nodeﬁciency-syndrome-(AIDS-) deﬁning illness in 3–5% of
HIV+ patients [25]. EBV positivity is signiﬁcantly correlated
with HIV disease status and subtypes of HIV-associated
lymphoma, generally involving extranodal tissues, in partic-
ular the gastrointestinal tract, lungs, liver, CNS, and bone
marrow. The overall incidence of EBV-positive cells in HIV-
related lymphomas is about 60%, even if the incidence varies
with the site and subtype of lymphoma.
2.3. EBV and Hematological Malignancies. EBV infection has
been associated with several hematopoietic cell tumors.
2.3.1. B-Cell Lymphomas. Systematic testing of a large panel
of B-cell lymphomas has shown that the EBV genome is
foundmainlyinhigh-gradelymphomas,thoughrarecasesof
partial EBV infection of low-grade B-cell lymphomas have
been observed [32].
Burkitt Lymphoma (BL). Burkitt lymphoma was ﬁrst de-
scribedinchildrenfromequatorialAfricabyDenisBurkittin
1958. It is a highly proliferative B-cell tumor that includes 3
variants: endemic (aﬀecting children in equatorial Africa and
New Guinea), sporadic (children and young adults through-
out the world), and immunodeﬁciency-related (primarily in
association with HIV infection) [33]. EBV has been detected
in virtually all cases of the endemic variant, in 15–20% of the
sporadic variant, and in 30–40% of the immunodeﬁciency-
related variant [34]. In all variants, irrespective of the EBV
status,constitutiveactivationofthec-myconcogenethrough
its translocation into one of the immunoglobulin loci is the
key factor in the oncogenesis of BL [33, 34]. The detection of
somatichypermutationsintheVregionoftheimmunoglob-
ulin genes and the phenotype of Burkitt lymphoma cells
indicate a germinal center cell origin of this lymphoma [35].
Most EBV-positive cases exhibit a highly restricted pattern
of expression of latent gene products, including only EBNA1
and the EBERs (Latency I). However, it has been recently4 Clinical and Developmental Immunology
reported that some cases, in addition to EBNA1 and the
EBERs, also express EBNAs 3A, 3B, and 3C, but still lack
EBNA2andthelatentmembraneproteins[36].Thispeculiar
restricted latency pattern has stimulated an intense debate
about the role of EBV in the pathogenesis of Burkitt lym-
phoma. A number of reports demonstrate that EBNA1 plays
a crucial role in the maintenance and replication of the viral
genome, but its oncogenic potential is still highly controver-
sial [34, 37]. As the EBERs are believed to possess antiapop-
totic activities, as well as the ability to induce the expression
ofIL-10,whichmaypromotetumorcellgrowthandsurvival,
it has been suggested that these RNAs may play an essential
role in the oncogenesis of Burkitt lymphoma [38]. More-
over, analysis of the chromosome breakpoints in the myc-
activating translocations indicates that these genetic changes
have occurredduring eithersomatic mutation orclass switch
recombination, which are both unique processes of germinal
centre cells [39]. In this regard, recent ﬁndings demonstrated
that peculiar subsets of endemic BLs show the presence
of an EBNA2-deleted virus genome, resulting in a high
Wp promoter activity and a constitutive BHRF1 expression.
These ﬁndings conﬁrm previous data obtained in mouse
models of c-myc-driven lymphomagenesis [40], where full
malignant transformation occurs only when a target cell
expressing a deregulated c-myc oncogene acquires comple-
mentary changes that counteract c-myc-driven apoptosis
[41]. It has been suggested that BHRF1 may be such comple-
mentary factor, thus providing the ﬁrst evidence implicating
a herpesvirus bcl2-like protein in viral oncogenesis [42].
Hodgkin’s Lymphoma (HL). Hodgkin’s lymphoma is the
most common EBV-associated lymphoma in Europe and
USA, with about 40% of EBV-positive HL cases [35]. Inter-
estingly, in the tumor tissue, only a small subset of cells, the
so-called Hodgkin-Reed-Sternberg (HRS) cells, are the EBV-
transformed tumor cells, primarily of B-cell origin [43],
while the majority of cells composing the tumor mass are
inﬁltrating lymphocytes (TILs). This indicates that HL has
already managed to generate an immunosuppressive envi-
ronment that allows tumor cells to grow despite extensive
homing of immune cells to the tumor site. Moreover, HRS
cellshavebeenshowntoproduceimmunosuppressivecytok-
ines, including IL-10, IL-13, and TGF-β [44, 45] and to allow
tumor immune escape by several mechanisms. As a result,
regulatory T (Treg) cell populations are enriched in HL
t i s s u e sa n da r ea b l et os t r o n gl ys u p p r e s sp e ri p h e r a lb l o o dc e l l
proliferation and cytokine secretion [46]. In addition to this
local immune suppression, selective systemic impairment of
EBV-speciﬁc T-cell responses might also contribute to HL
development.Alongtheselines,HLpatientshavediminished
EBNA1 speciﬁc CD4+ T-cell responses, while they maintain
CD8+ T-cell responses against other latent and lytic EBV
antigens [42]. These ﬁndings suggest that immunotherapeu-
tic approaches should be developed to correct both the selec-
tive systemic immune impairment and tumormicroenviron-
ment speciﬁc deﬁciencies in EBV-speciﬁc immune control.
Since the tumor cells seem to have no defects in antigen
processing for MHC class I (MHC-I) presentation, inter-
ventions able to correct the selective systemic loss of EBV
speciﬁc T-cell responses and to overcome the local immune
suppression in the tumor tissue should be explored as treat-
ments of this EBV-associated malignancy and ideally such
modalities could be used for prevention in high-risk popu-
lations.
2.3.2. Tumors Derived from T and NK Cells. The rate of asso-
ciation of the virus with these tumors is so high that the ab-
sence of the virus virtually excludes diagnosis. All described
entities, mostly encountered in Japan and South-East Asia,
are closely related and can also arise in a single patient.
Peripheral T-Cell Lymphoma, NK Tumors, and EBV-Asso-
ciated Haematophagocytic Syndrome (HS). HS is frequently
observed in infants with immune deﬁciencies in association
with primary or chronic EBV infection. In these patients, T-
cell lymphocytosis and EBV-positive T cells are frequently
observed in the blood and tissues. Aﬀected individuals are
at high risk of subsequent or concurrent development of
EBV-positive T-cell lymphomas and NK cell tumors [23].
Detection of EBV in either normal T lymphocytes or tumor
cells establishes the diagnosis.
NK Leukaemias. NK leukaemias are mainly observed in ad-
olescents of the Far East in association with hepatosple-
nomegaly and multiple cutaneous lesions [24]. Histological
examination identiﬁes large granular lymphocytes express-
ing NK markers. The rate of EBV association approaches
100%.
Extranodal NK/T Cell Lymphoma (NKTCL). Extranodal
NK/T cell lymphoma of the nasal type consists of an angi-
oinvasive and angiodestructive lymphoid inﬁltrate with ne-
crosis that aﬀects and can cause destruction of the nasal
cavity and of several anatomical structures of the midface
[47]. Extranodal NKTCL represents the major group of
mature NK cell neoplasms in the recently revised WHO clas-
siﬁcation of hematolymphoid tumors [48]. Importantly,
EBV is present in virtually all NKTCL cases (EBER-positive,
EBV proteins rarely expressed, with a more or less complete
latency II pattern) [49]. Circulating EBV DNA load is an
important prognostic factor in this setting, and plasma EBV
DNA levels can also be used for disease monitoring [50].
These tumors are more frequently observed in Asian and
Central and South American populations, where they can
accountforupto10%ofallnon-Hodgkin’slymphomas[51].
Inﬂammatory Pseudotumor-Like Follicular Dendritic Cell
Tumor (IPLFD). IPLFD preferentially develops in liver and
spleen, or more rarely in lymph nodes. This exceptional
tumor is characterized by a prominent inﬂammatory back-
ground including numerous lymphocytes and plasma cells,
among which neoplastic follicular dendritic cells (FDCs) can
be identiﬁed [52]. Viral infection is readily established with
an EBER assay showing intense signals in all cancer cells;
LMP1 staining, although consistently positive, is generally
weak. Due to the consistent association with EBV, diagnosis
of this entity requires detection of the virus.Clinical and Developmental Immunology 5
2.4. EBV and Nasopharyngeal Carcinoma (NPC). Nasopha-
ryngeal carcinoma is classiﬁed as a malignant neoplasm aris-
ing from the mucosal epithelium of the nasopharynx, most
often within the lateral nasopharyngeal recess or fossa of
Rosenm¨ uller. There are three histopathologic subtypes of
NPC: a well-diﬀerentiated keratinizing type, a moderately-
diﬀerentiated, nonkeratinizing type, and an undiﬀerentiated
type, which typically contains large numbers of noncancer-
ous chronic inﬂammatory lymphocytes. The undiﬀerenti-
ated form is the most common and also the most strongly
associated with EBV infection. NPCs are rare in most coun-
tries, especially in Europe and North America (incidence
below 1/100,000), whereas it has a high incidence in several
areas in Southern China, especially in the Cantonese region
around Guangzhou, where the incidence is approximately of
30–80/100,000 cases per year and where the diet probably
plays a carcinogenic role. EBV is strongly associated with
undiﬀerentiated nasopharyngeal carcinomas, in which virus
infection is observed virtually in 100% of the cases [53], and
epithelialEBVinfectionisalsowelldocumentedinvitro[54].
Accordingly, following primary infection in the oropharynx,
EBV persists in numerous anatomical sites including pha-
ryngeal tonsils, adenoids, lymph nodes, and peripheral
blood, where the virus is present in small resting memory
B cells with latent gene expression being virtually absent or
limited to EBER, LMP2a, and EBNA1 [55]. Despite available
evidence, the presence of EBV within normal epithelial cells
in vivo remains a matter of debate. Some authors demon-
strated the presence of EBV in desquamated squamous
and tonsillar epithelium [56, 57]. In contrast, other studies
have reported no virus in the same cells or unequivocal
evidence of EBV-infected tonsillar epithelial cells by EBER
ISH and/or LMP1 immunostaining [58–60]. Although the
demonstration of virus latency and replication in vivo is still
under investigation, it is well known that vigorous humoral
and cellular immune responses control the proliferation of
EBV-infected cells in healthy virus carriers [61, 62]. Early
after the discovery of EBV association with NPC, a deregula-
tion of the EBV-speciﬁc immune response with elevated IgA
titers against the virus was noted [63]. This indicated that
the immune response at the site of tumor development was
abnormal, and that the tumor might inﬂuence its microen-
vironment to facilitate neoplastic cell growth. Accordingly,
recent studies supported the notion that local immune
suppression rather than a systemic deﬁciency in EBV-speciﬁc
immune control may contribute to NPC development.
Indeed, both nonspeciﬁc (NK-cell-mediated) and EBV-spe-
ciﬁc (T-cell-mediated) responses were shown to play impor-
tant roles during primary infection, while EBV-speciﬁc T-
cells appear to be critically involved in restraining the
proliferation of EBV infected cells during life-long persistent
infection. On these grounds, some studies conﬁrmed that
EBV-speciﬁcTcellsaremaintainedinhealthycarriersatrela-
tively high frequencies throughout life [64], whereas EBV-
speciﬁc CD4+ and CD8+ responses might be reactivated
from peripheral blood of NPC patients [65, 66]. In partic-
ular, clinical and immunologic responses were observed by
Comoli et al. after EBV-targeting CTL therapy in patients
with radiotherapy- and chemotherapy-resistant stage IV
NPCs [67]. Importantly, they conﬁrmed that, despite immu-
nosuppressive treatments, it is possible to reactivate and
expand ex vivo these eﬀectors, suggesting that reconstitution
of EBV-speciﬁc immunity could also be a useful strategy in
the management of NPC. Interestingly, a signiﬁcant immune
suppression can also be observed at the tumor site. In-
deed, even though LMP1- and LMP2-speciﬁc CTLs were
enriched in tumor inﬁltrating lymphocytes, their cytotoxi-
city and cytokine secretion could be impaired, resulting in a
local immunomodulation. Particularly, the high presence of
natural Tregs (CD4+CD25+FoxP3+)[ 68] and the production
of galectin-9-carrying exosomes in NPC patients [69]c o u l d
suppressEBV-speciﬁcimmuneresponsesintumortissues.In
addition to active T cell suppression at the tumor site, the
expression of immune suppressive cytokines, such as inter-
leukin 10 (IL-10), has also been related with an immune
escape mechanism, partly because EBV-encoded LMP1 can
induce IL-10 [70]. However, the importance of immune
suppressive cytokines seems limited in NPC [71]. In addi-
tion, the eﬃciency with which NPC can present antigens
to T-cells might also be compromised. While earlier studies
based on a limited number of NPC cell lines suggested that
antigen processing for MHC-I presentation was intact in
NPCcells[72],amorerecentstudyonprimarytumortissues
suggested that the MHC-I antigen processing machinery is
downregulated in the majority of tumors [73]. Together,
these data suggest that NPC cells impair EBV-speciﬁc im-
mune control locally, while allowing eﬃcient systemic im-
mune responses against this virus.
3 .EB VI nf ec tio nandt h eI m m uneS ys t e m
The immune system preserves the integrity of its host by
recognizingandresistinginvaders;thefrequencyandseverity
of EBV-associated diseases, particularly in immunocom-
promised individuals, highlight the critical importance of
immune responses in controlling this virus infection. It is
well known that the adaptive arm of the immune system
plays a pivotal role in protective immunity against EBV [74,
75]. Nevertheless, emerging data suggest that also the innate
compartment may cooperate to the immune response [76–
78], mounting a highly coordinated cascade of molecular
interactions, which not only activate but also heighten the
potential to bias the ensuing adaptive phenotype. Since the
role of the innate immunity in EBV infection is still unclear,
our aim is to mainly review current knowledge in this
respect, with a particular focus on the contribution of innate
immunecellsincontrollingtheprogressionofvirusinfection
towards the oncogenic phenotype.
3.1. Innate Immunity and EBV Infection. Understanding the
importance of host innate immune responses in the context
of EBV infection will allow a better understanding of how
EBV can persist in the infected host to promote cell transfor-
mation [79]. Intriguingly, EBV interacts with diﬀerent cell
types that are crucial mediators of innate immune responses
(Figure 1), including NK cells, neutrophils, and monocytes/
macrophages. Moreover, the virus can also infect epithelial6 Clinical and Developmental Immunology
cells that play an important role in the innate resistance to
diﬀerent pathogens [78].
3.1.1. NK Cells. NK cells are innate lymphocytes that play a
pivotal role in the control of infections and in the immune
surveillance against transformed cells [80]. In particular,
early after primary viral infections NK cells are thought to
limit the viral burden until virus-speciﬁc T cells are able to
eliminate the infection or control viral titres at low levels.
Notably, NK cells produce cytokines such as interferon-γ
(IFN-γ), proliferate, and increase their cytotoxicity upon
activation by both myeloid and plasmacytoid dendritic cells
(DCs) [81]. Therefore, DCs seem to activate NK cells early
after infection in order to restrict pathogen replication
until the adaptive immune system establishes long-lasting
immune control. Two main functional NK cell subsets have
been distinguished in humans: CD16+CD56dim NK cells,
which readily lyse susceptible target cells, but secrete only
low levelsofcytokines afteractivation;andCD16−CD56bright
NK cells that produce large amounts of cytokines upon
stimulation and acquire cytotoxicity only after prolonged
activation[82].CD16+CD56dim cellsconstituteabout90%of
human circulating NK cells, whereas CD16−CD56bright NK
cells represent <10% of the peripheral blood NK cell pool.
However, in secondary lymphoid organs such as tonsils and
lymph nodes, the CD16−CD56bright NK cells are the dom-
inant subset [83]. Interestingly, viral double-stranded RNA
(dsRNA) products, including EBV convergent transcription
of LMP1 and LMP2 RNA and EBERs dsRNA stem-loop
structures [84], trigger monocyte toll-like receptors (TLRs)
inducing maturation of DCs, which through the production
of high levels of IL-12, activate CD16−CD56bright NK cells
more eﬃciently than other mature DC preparations [85].
Because the tonsils are the primary site of EBV infection,
the DC-NK cell crosstalk could trigger NK cells to limit B
cell transformation during EBV infection (Figure 1). Indeed,
in vitro virus-activated DCs elicited 50-fold stronger IFN-γ
secretion from tonsil NK cells than from peripheral blood
NK cells; these high IFN-γ concentrations delayed latent
EBV antigen expression, inhibit B-cells transformation, and
decrease their proliferation during the ﬁrst week after EBV
infection in vitro [86]. In addition to its direct antiviral
activity, IFN-γ secreted by DC-activated NK cells might
also shape the EBV-speciﬁc adaptive immune response by
favouring a Th1-polarization (Figure 1), which is observed
in EBV-positive individuals. These in vitro ﬁndings suggest
that humans have a strategically well-positioned population
of NK cells, which directly hampers pathogen entry at
mucosal sites and might restrict EBV infection until adaptive
immunity establishes immune control of this persistent and
oncogenic human pathogen [86]. However, only few in vivo
examples support this hypothesis [85], and little is known
about NK cell contribution to EBV persistence, thus still
leaving several open questions.
In addition to protective T-cell immunity in healthy
v i r u sc a r r i e r s ,s e v e r a ll i n e so fe v i d e n c es u g g e s tar o l ef o r
innate lymphocytes in the resistance against EBV-associated
malignancies. For example, in male patients with X-linked
lymphoproliferative disease (XLP), who frequently succumb
after primary EBV infection as a consequence of EBV-driven
lymphomas, a mutation in the SAP (signalling-lymphocyte
activation-molecule-(SLAM-) associated protein) gene leads
to defective recognition of EBV-transformed B cells by T
and NK cells [87]. Although the biologic eﬀects of SAP
mutations are not limited to alterations in NK cell function,
this defective recognition most likely contributes to loss of
EBV speciﬁc immune control. Furthermore, during EBV
latency, the virus develops several mechanisms of immu-
noescape from this innate immunity cell subset, including
the inhibition of NK cells activation through Epstein-Barr-
virus-induced gene 3 (EBI3). EBV-transformed B-lympho-
cytes express at high levels the EBI3 protein, which is
related to the p40 subunit of IL-12 and associates with p35
and, consistent with a potential immunosuppressive activity,
a peptide derived from EBI3 has been shown to bind HLA-
G, which is the ligand of inhibitory receptors expressed
on NK cells and CTLs [78, 88]. Moreover, in situ analysis
revealed EBI3 overexpression in neoplastic cells of individu-
als aﬀected by HLs and LMP1-positive EBV-associated lym-
phoproliferative disorders (including posttransplant LPDs
and nasal-type NK/T-cell lymphomas) [89], thus supporting
its hypothetical role in regulating immune response against
EBV. Finally, NK cells seem to play a fundamental role in
T-cell-depleted HLA-haploidentical HSCT (hematopoietic
stem cell transplantation), indeed in the early posttransplant
period, lymphocytes in the peripheral blood are mostly NK
cell populations and the antileukemia eﬀect is mediated by
“alloreactive” (i.e., KIR/HLA-mismatched) NK cells origi-
nated from donor HSCs [90]. Nevertheless, in these patients
an increase in EBV load is often observed, until they receive
donorEBV-speciﬁccytotoxicT-lymphocytes,suggestingthat
in this setting NK cells are not able to control EBV DNAemia
[91].
3.1.2. Phagocytes. In addition to the clearance of virions or
virally infected cells by phagocytosis, both neutrophils and
monocytes elicit a respiratory burst when exposed to viruses
and can produce a variety of mediators, some of which have
antiviral activity [92]. Moreover, EBV genome was detected
in non-B-cells, including phagocytes, of most patients
with EBV-lymphoproliferative disorders [93]. Interestingly,
monocytes and macrophages are involved in the uptake of
smallvesicles calledexosomes, containing viralmiRNA. Exo-
somes are nanosized membrane vesicles released from a wide
variety of cells that have immune stimulatory, inhibitory,
or tolerance-inducing eﬀects, depending on their cellular
origin [94]. Exosome secretion protects miRNA by RNases
degradation, thus miRNA secreted by EBV-infected cells are
transferred to uninfected cells and could act also in EBV−
recipients [95]. It has been demonstrated that exosomes
of diﬀerent origin and with function can selectively target
diﬀerentimmunecellsinvitro.Inthisregard,whileexosomes
derived from EBV-transformed lymphoblastoid B-cell lines
target preferentially B cells, DC-derived exosomes are mainly
associated with monocytes, which actively engulf these vesi-
cles [94]. Thus, exosomes play a role during the early phases
of EBV infection, also involving innate immunity-related cell
types, that otherwise would not be directly targeted by theClinical and Developmental Immunology 7
virus. We will now consider separately the main subsets of
“professional” phagocytes and their interplay with EBV.
Neutrophils. As in the case of most viral infections, a blood
neutrophil increase is observed during the initial phases of
EBV infection, whereas a transient episode of acute neu-
tropenia is often seen in IM patients during the third and
fourth weeks of illness [96–98]. In vitro studies showed that
the interaction of EBV with these cells causes an abortive
infection, where the virus penetrates the cells and is trans-
ported to the nucleus, even if this is not followed by gene
expression. Infected neutrophils rapidly die by apoptosis,
probably via Fas triggering by its ligand that is upregulated
upon EBV infection [99]. EBV particles can bind to 30% of
neutrophils,althoughthesecellsdonotexpressthecanonical
EBV receptor CD21 [100], and this binding is suﬃcient to
trigger the release of inﬂammatory mediators. Moreover,
EBV induces neutrophils to produce IL-1α and IL-1β
(Figure 1),butthisiscounteractedbyaconsiderablystronger
inductionofIL-1Rantagonistthatneutralizestheproinﬂam-
matory activity of IL-1 [77]. IL-1Ra to IL-1 ratio of 10–100 is
necessary to inhibit the IL-1 eﬀects on target cells by 50%
[101]. In response to EBV infection, the levels of secreted
IL-1Ra in neutrophil culture supernatants are approximately
3600 and 610 times more than those of IL-1α and IL-1β,
respectively [102], an indication of a predominant IL-1Ra
response. By favouring the secretion of IL-1Ra, EBV may
thereby shift the tightly regulated balance between IL-1 and
IL-1Raproduction.ExpressionofthechemotacticfactorsIL-
8 and macrophage inﬂammatory protein (MIP)-1 was also
detected in EBV-infected neutrophils [103]. The production
of these cytokines by neutrophils could be involved in the
recruitment of leukocytes in the lymphoid tissues and allow
EBV a direct access to B cells. Two additional biological
functions of neutrophils are known to be primed by EBV:
the biosynthesis of leukotriene (LT) B4 and the production
of reactive oxygen species [77]. LTB4 exerts a wide array
of immunoregulatory activities (Figure 1). Among others,
it stimulates locomotion and chemotaxis of phagocytes,
m o d u l a t e sl y m p h o c y t ea sw e l la sp h a g o c y t ef u n c t i o n sa n di s
alsoinvolvedintheregulationofcytokinesproduction[104].
In addition, LTB4 enhances antitumor activities of NK cells
and was recently reported to also exert antiviral activities
[105]. Production and release of reactive superoxide anion,
alsoknownasrespiratoryburstactivity,isanotherimportant
function involved in destruction of viral particles. The fact
that neutrophils become more responsive to the release of
LTB4 and O
−
2 anion after interacting with EBV constitutes
an alternative route for the immune defence to counteract
viral invasion [77]. Therefore, the interaction of EBV with
neutrophils has opposing inﬂuence on the initiation of
immunity. Some of these eﬀects such as the secretion of
IL-1, IL-8, MIP-1α, LTB4, and reactive superoxide anion,
promote the development of EBV-speciﬁc immunity, while
the upregulation of IL-1R and the induction of apoptosis in
neutrophils inhibits anti-EBV immune responses [78].
Monocytes, Macrophages, and Dendritic Cells. In antiviral
immune response, similarly to neutrophils, monocytes are
rapidly recruited to sites of viral infection and were shown
to adhere to ﬂu-infected cells [106]. Monocytes are also
known to play a key role in the initiation of speciﬁc immune
responses. Moreover, they may contribute to host defence by
mediating antibody-dependent cellular cytotoxicity (ADCC)
via activation of NK cells. Episodes of monocytopenia were
observed during the acute phase of IM [107]. In addition,
patients with EBV-associated HL often show a deﬁciency
in monocyte-mediated ADCC, suggesting that monocyte
functions are aﬀected during the course of EBV infection
[77], as also demonstrated by the reduced phagocytic
activity observed in EBV-infected monocytes [108]. This
eﬀect was probably caused by the impairment of protein
kinase C (PKC) activity. EBV infection was found to prevent
PMA-induced translocation of PKC and by altering the
subcellular localization of the receptor for activated C
kinase (RACK) 1 [109]. RACK1 is an essential anchor-
ing protein that interacts and translocates with activated
PKCs in response to a stimulus. Interactions of RACK1
with the EBV-encoded ZEBRA protein may inhibit PKC
translocation and activation [77]. EBV infection inhibits
also the functional ability of macrophages to respond
to bacterial challenge [110] by reducing their phagocytic
potential. The alteration of the phagocytic process is just
an example of the EBV versatility exhibited to target the
multiple facets of monocytes and macrophages antiviral
activities.
Moreover, EBV directly binds the surface of approxi-
mately the 20% of monocytes, involving cellular receptors
that are still not well characterized. Entry and translocation
of EBV particles into the nucleus were visualized by electron
microscopy and conﬁrmed by the detection of EBV genome
in isolated nuclei [108]. Interestingly, nuclear levels of viral
genomic DNA were found to increase with time, suggesting
that replication may actually occur in monocytes. Further-
more, although EBV propagation is mainly due to cell-cell
contact that primarily involves B cells and epithelial cells,
also monocytes and macrophages may participate in the
transport of the virus and favour its propagation [111],
especially within the oral epithelium, where EBV actively
replicates and is released into the saliva [112]. The outcome
of monocyte/EBV interaction is strongly inﬂuenced by the
stage of diﬀerentiation of monocytes. Indeed, EBV infection
inhibits the development of DCs from monocyte precursors
[113] and the exposure to EBV induces apoptosis of a large
proportion of monocytes cultured in the presence of GM-
CSF and IL-4. Binding of EBV to monocytes through the
v i r a lm e m b r a n ef u s i o nc o m p l e xm a yb es u ﬃcient to trigger
events that will eventually lead to cell death. By inhibiting
the diﬀerentiation of monocytes into mature DCs, EBV
temporarily halts the onset of immune responses during
primary infection, creating a time window for eﬃcient viral
replication. This permits the accumulation of a large pool of
virus infected B-lymphocytes and allows their access to the
memoryB-cellcompartment,interfereswiththefunctionsof
DCsduringtheinitiationofvirus-speciﬁcimmuneresponse,
and modiﬁes the proﬁle of secreted cytokines in order to
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In this context, EBV has evolved over the millennia to
modulate the cytokine network of the host in order to be
not completely eliminated after primary infection and to
promote its life-long persistence. Puriﬁed gp350/220, the
major glycoprotein component of EBV envelope, induces
secretionofIL-1,IL-6,andTNF-αby monocytes [77].Inthis
regard, during the course of primary infection, IL-1 and IL-
6 are frequently detected in the serum and in tonsils of IM
patients [114]. In addition, both IL-1 and IL-6 are actively
secreted by EBV-immortalized B cells and have been shown
to act as autocrine/paracrine growth factors for these cells
(Figure 1). TNF-α can increase macrophage cytotoxicity,
mediate natural cell cytotoxicity, and also participate in
the regulation, maturation, activation, and lymphocytes
proliferation. TNF-α was also reported to elicit antiviral
activities against both RNA and DNA viruses (reviewed in
[77]). Moreover, recombinant TNF-α was found to inhibit,
in a dose-dependent manner, the proliferation and diﬀer-
entiation of both EBV-activated and- transformed human B
cells [115]. Therefore, it is not at all surprising that levels of
TNF-α a r ed e t e c t e di nt h es e r u mo fI Mp a t i e n t s[ 114], an
indication of the importance of this cytokine in the ongoing
antiviral response. However, the entire virus inhibits the
secretion of TNF-α by monocytes and macrophages, and,
interestingly,neitherperipheralbloodmononuclearcellsnor
puriﬁed monocytes showed increased secretions of TNF-α in
response to EBV [77]. EBV downregulated the cellular levels
of TNF-α mRNA transcripts, suggesting that it may elicit its
suppressive action at the transcriptional level. Furthermore,
the virus inhibited the synthesis of the chemokine MIP-1α,
thus reducing the recruitment of leukocytes. EBV was also
found to induce the production of granulocyte-macrophage
colony-stimulating factor (GM-CSF) upon adsorption to
the cell surface of monocytes [116]. Secretion of GM-
CSF by monocytes was shown to synergize with EBV to
enhance release of IL-8, MIP-1, and IL-1 by neutrophils
(Figure 1), as well as the magnitude of EBV priming eﬀecton
superoxide and LTB4 production. EBV diﬀerentially aﬀected
the production of leukotrienes and prostaglandins (PGs) in
monocytes. The direct interaction of EBV gp350 with the
cell surface is suﬃcient to prime monocytes for an enhanced
release of LTB4. A completely opposite eﬀect is extended
on PGs production [117]. PGs, such as PGE2, are potent
vasodilators, hyperalgesic agents, and also pyrogenic sub-
stances. Both IL-2 and IFN-γ production by Th1 cells were
downregulated by PGE2 via increased levels of cAMP [118].
In contrast, PGE2 favours Th0-like response to shift towards
a Th2-like pattern and promotes the synthesis of IL-4, IL-5,
andIL-10bythesecells[119].Inaddition,PGE2canregulate
humoral responses by increasing the immunoglobulin class
switching, particularly IgE in B lymphocytes. PGE2 is also
known to exert antiviral activities both in vitro and in vivo.
EBV suppresses the production of PGE2 by downregulating
the LPS-induced expression of COX-2, without altering
that of constitutive COX-1. Finally, the lytic gene BARF1
neutralizes the proliferative eﬀects of CSF-1 on monocytes
and inhibits poly(I-C)-induced secretion of INF-α by these
cells [120], interfering with IFN-dependent antiviral eﬀects
of innate immunity [78]. These observations show that
EBV has developed a perfect way of rapidly promoting the
expression of its own genes while simultaneously shutting
down the transcriptional programs of the cells.
3.1.3. Epithelial Cells. Epithelial cells have an important role
in the innate resistance to diﬀerent pathogens and represent
a preferential target of EBV infection, even if inv i v oanalysis
revealed no evidence of EBV infection in salivary glands
and only rare positivity in normal squamous epithelial cells
at the tongue margin [121]. In this regard, kinetics studies
performed in healthy individuals underlined the potential
importance of epithelial cells in EBV replication and shed-
ding, assuming that B cells sporadically release virus that
infects epithelial cells, which in turn may contribute to
amplifytheamountofshedvirus;thusthemouthisprobably
not a reservoir of the virus, but a conduit through which a
continuous ﬂow stream of virus passes in saliva [122]. How-
ever,sinceEBVcanbedetectedinmostundiﬀerentiatedNPC
and in precancerous lesions, EBV infection has long been
postulated to play an important role in NPC pathogenesis.
It is worth mentioning in this respect that an in vitro model
of EBV infection in premalignant nasopharyngeal epithelial
cells was described by Tsang and colleagues [123]. The
direct infection of epithelial cells requires the interaction
betweenEBVglycoproteinsgHgLandcellularανβ6andανβ8
integrins [124]. In addition, an alternative process named
“transfer infection” was proposed to explain the interplay
between EBV and epithelial cells: the infection of memory
B cells determines CD21-mediated capping of virus and
activation of adhesion molecules, which in turn facilitates
conjugate formation between B cells and epithelial cells
and then the subsequent entry of EBV into epithelial cells
[125]. EBV-positive cells, such as EBV-infected B-cells and
EBV-carrying carcinoma cells, secrete exosomes enriched in
LMP1 [126], which may interact with surrounding cells,
in particular suppressing neighbouring T cells [127], thus
contributing to immune modulation [128]. Moreover, in
EBV-infected epithelial cells LMP2A and LMP2B accelerated
the turnover of IFN receptors through processes requiring
endosome acidiﬁcation [129]. This function forms part of
EBV strategy to limit antiviral responses. Interferons consti-
tute a ﬁrst line of defence against viral infection, serving to
integrateinnateandadaptiveimmuneresponsesandlimiting
the replication and spread of viruses. IFNα and IFNβ (type
I IFNs) block viral replication by inhibiting cellular protein
synthesis, stimulating the expression of proinﬂammatory
cytokines and orchestrating cellular immune responses.
Similarly, IFN-γ (type II IFN) has a key function in “ﬁne-
tuning” the adaptive immune response. Whereas IFN-α and
IFN-β share a common receptor, IFNAR, IFN-γ binds to
IFNGR. The BZLF1 protein of EBV has been reported to
downregulate transcription of the IFNGR during viral entry
into lytic cycle, thereby protecting lytically infected cells
from immune surveillance. Similarly, LMP2A and LMP2B
attenuate IFN responses by inﬂuencing IFNAR and IFNGR
stability (Figure 1), promoting their ubiquitination and the
traﬃcking from endosomes to lysosomes. The ability of
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example of a successful viral strategy for circumventing the
innate immune response, an eﬀect that is generally exploited
in persistent virus infections but, in the context of oncogenic
viruses such as EBV, may also contribute to tumor develop-
ment [129].
3.1.4. Toll-Like Receptors. Innate immunity uses several pat-
tern recognition receptors to sense pathogen-associated mo-
lecular patterns (PAMPs). The TLRs are the most studied
pattern recognition receptors, and activation by pathogen
components leads to robust immune response. TLR activa-
tion has probably multiple downstream eﬀects during pri-
mary EBV infection, some of which may favour viral latency
or reactivation and other may facilitate immune control.
TLR2 was reported to recognize several PAMPs conserved
on virions from diﬀerent members of human herpesviruses.
TLR9 is an important receptor for nucleic-acid-containing
unmethylated CpG motifs present in both bacterial and viral
DNA, whereas TLR7 senses single-stranded RNA [130]. A
rapid detection of EBV particles during primary infection
and the detection of secreted components or reactivated
virus from EBV-infected cells are crucial for an eﬃcient con-
trol of EBV infection. Intact viral particles are recognized by
the membrane surface TLR2 (Figure 1)[ 131], likely through
the interaction with gp350, the major envelope glycoprotein
whichmediatesalsoEBVentryintoBcells[132].Inaddition,
TLR2 is involved in the recognition of the unstructural
protein dUTPase, which determines the activation of NF-κ
B via MyD88-dependent signalling cascade and induces
expression of proinﬂammatory cytokines in macrophages
[133]. Following viral entry into the cells, viral DNA is
subsequently recognized by TLR9 (Figure 1). Such dual
interactions, through TLR2 on cell membrane and by intra-
cellular TLR9, lead to a rapid production of IL-8 to initiate
an eﬀective immune response. Production of MCP-1 and IL-
10 by monocytes in response to EBV is mainly dependent on
TLR2ratherthanTLR9[134].Therefore,becausemonocytes
express low levels of TLR9, it seems plausible that they have
acquired the ability to use one TLR, in this case TLR2, to
produce diﬀerent cytokines to better respond to EBV before
its entry into the cell. On the contrary, plasmacytoid DCs
(pDCs) seem to recognize the virus primarily through TLR9
[134], which, in combination with TLR7 activation, could
potentiatetheproductionoftypeIIFNsviaIRF7,promoting
the activation of NK cells and IFN-γ producing CD3+ Tc e l l s
[135].Suchrecognitionbyasinglecelltypethroughmultiple
TLRs could then ensure an eﬃcient innate response, but may
also optimize the detection of the virus once it has escaped
recognition by membrane TLR or intracellular TLR follow-
ing entry into the cytosol. However, EBV has developed the
ability to escape the innate immune response by downregu-
latingTLR9transcription[110].Notably,thevirusexertsthis
activity by using its major oncoprotein LMP1 via activation
ofNF-κBsignalling.PrimaryB-cellinfectionbyEBVresulted
in an impairment of TLR9 pathway functionality, correlated
with a decrease of TLR9 mRNA and protein levels in com-
parison with noninfected primary B cells [79]. In addition to
TLR9,Fathallahetal.observedthatEBVinfectionofprimary
B cells led to inhibition of TLR2 transcription and function-
ality[79].Previousdatashowedthatthemajoroncoproteins,
E6 and E7, from the high-risk HPV type 16 inhibit the
expression of TLR9. Thus, the ability to downregulate TLR9
expression is probably a shared property among DNA
tumor viruses [136]. Interestingly, the low-risk HPV types,
associated with benign cervical lesions, are unable to alter
TLR9 expression, suggesting that TLR9 downregulation is an
event exclusively associated with carcinogenic viruses [79].
The EBV noncoding RNAs, EBV-encoded RNA 1
(EBER1), and EBER2 are expected to form dsRNA-like
structures [137]. EBER is the most abundant viral transcript
in latently EBV-infected cells and binds to several cellular
proteins including RNA-activated protein kinase (PKR),
ribosomal protein 22 (L22), lupus erythematosis-associated
antigen (La), and retinoic acid inducible gene I (RIG-I;
reviewed in [138]). EBER exists in the sera of patients with
active EBV infections and induces type I IFNs and inﬂam-
matory cytokines through TLR3-mediated signalling, which
is a sensor of viral double-stranded RNA (dsRNA) [84]. This
may account for the pathogenesis of active EBV infections
that are characterized by cytokinemia. Furthermore, EBER1-
treated DCs may induce primary immune responses, sug-
gesting that during active infection, EBER1-mediated TLR3
stimulation is responsible for immune activation by EBV.
TLR3 is predominantly expressed by DCs, but also by CD8+
T cells and NK cells, thus, circulating EBER1 could induce
the activation of both DCs and T cells (Figure 1)[ 84].
These ﬁndings suggest that immunopathologic alterations
that are caused by active EBV infections could be attributed
to TLR3-mediated cytokinemia induced by EBER1, and that
circulating EBER1 could be a potential target for therapeutic
agents [84]. Moreover, EBERs may have several roles in EBV-
driven tumorigenesis: EBER1 and EBER2 contribute to the
clonal proliferation of EBV-negative BL cells in soft agar,
promote tumorigenicity in SCID mice, upregulate the bcl-2
oncoprotein, induce resistance to apoptosis, and favour the
maintenance of malignant phenotypes in BL cells. EBERs
inducetheexpressionofIL-10inBLcells,insulin-likegrowth
factor 1 (IGF-I) in gastric and NPC cells. In BL cells, EBERs
prevent IFN-α-mediated apoptosis, while in epithelial cells
these RNAs confer resistance to Fas-mediated apoptosis by
blocking PKR activity. EBERs also play critical roles in the
growth transformation of B lymphocytes [84, 138].
EBV is also able to induce the expression of cellular
miRNA [131], in particular LMP1 signalling, through NF-κ
B and AP1, stimulates the expression of cellular miR-155,
which in turn targets intermediates of innate immune sig-
nalling pathways [139]. In addition, during latency, the vi-
rus induces miR-146, involved in the attenuation of type
I IFN production in macrophages [140], and miR-21 that
negatively regulates TLR4 signaling [141].
Given the fact that B-cell activation and proliferation
require the stimulation of TLR, it is possible that TLR
ligand-bearingpathogens,suchasbacteriacolocalizedatsites
of EBV infection or replication (i.e., in tonsillitis during
infectious mononucleosis), might favour EBV establishment
and spread by increased proliferation of infected B cells.
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possibly aggravate PTLD by triggering TLRs on EBV infected
B cells and thereby supporting their proliferation or modify-
ing lytic EBV reactivation. Likewise, microbial infection may
be a cofactor for EBV-associated BL, which mainly occurs in
regions where malaria is endemic. EBV itself is a source of
endogenous ligands of TLRs and other pattern recognition
receptors (PRRs) and might be capable of triggering TLR9,
mediated by hypomethylated CpG motifs in the viral DNA
genome [142].
Understanding TLR implications during early and acute
phasesofEBVinfectionmustthereforebeinvestigatedtofur-
ther develop strategies to treat EBV infection, especially in
immunosuppressed or autoimmune disease patients, in
which EBV was suggested to exacerbate clinical symptoms
[134].
3.2. Adaptive Immunity and EBV Infection. The recognition
of antigens and their proper presentation and processing
lead to the activation of speciﬁc adaptive immune responses
that ultimately control the invading infectious agents. The
central feature of immune memory is the ability of memory
cells to mediate faster, stronger, and more eﬀective responses
to secondary pathogen challenges than na¨ ıve cells. In this
respect, humoral and cellular immunity play a critical role in
controlling both the primary [143, 144] and persistent [143,
145] phases of virus infection. In particular, EBV stimulates
strong humoral responses to some lytic cycle proteins: IgM
and developing IgG responses to nucleocapsid and envelope
proteins are in fact detectable in primary EBV infection.
Moreover, IgG responses to some of the immediate early and
early lytic cycleproteins andto the latentprotein EBNA1 and
2 are also usually detectable, together with neutralizing anti-
bodies directed against gp350. Therefore, humoral responses
play an important role in controlling the spread of the virus
in the late phases of infection, while cellular immunity is
fundamental in controlling both the primary and persistent
phases of EBV propagation. More precisely, cytotoxic T lym-
phocytes (CTL) are the major determinants in the control of
acute EBV infection [146, 147] and are directed against both
lytic and latent antigens [148]. More than 44% of the total
CD8+ T cells in acute infection are speciﬁc for a single lytic
EBV epitope, and most of these epitope-speciﬁc cells have an
activated/memory phenotype [149]. Conversely, in the late
stages of infection, the frequency of epitope-speciﬁc CD8+
T cells selectively increases against latent EBV proteins, con-
ﬁrming that CTLs are the most important cells for limiting
infection in the convalescent phase of virus infection [149].
4. ImmunotherapyApproaches against
EBV-AssociatedMalignancies
The development of malignancies associated with EBV is
largely favored by an underlying defect in EBV-speciﬁc CTL
immunity and function. Therefore, much work has been
focused in the last years on the reconstitution of CTL immu-
nity to EBV in transplanted patients, who are at increased
risktodevelopPTLDasaconsequenceofiatrogenicimmune
suppression. Moreover, recent data indicate that other EBV-
associated diseases such as NPC, HL, BL, and chronic active
EBV infections (CAEBV) can potentially be treated with
immunotherapeutic approaches.
4.1. EBV-Targeting Vaccines in Virus-Associated Malignancies.
To date, the experience with human EBV vaccines is lim-
ited [150, 151] and, although potentially useful to prevent
EBV associated malignancies, vaccines providing life-long
immunity against primary EBV infection might be unfea-
sible, considering that the type of immunity required to
prevent repeated infection through mucosal surfaces is not
clearly deﬁned. Moreover, repeated infections with diﬀerent
EBV strains have been described [152], suggesting that the
natural immune response to EBV is not suﬃcient to pro-
tect healthy EBV-positive individuals from recurrent infec-
tions. Nevertheless, it was clearly demonstrated that the risk
of developing HL is 4-fold higher after resolution of IM,
whichissymptomaticofanabnormalprimaryEBVinfection
and then of a massive expansion of EBV-speciﬁc T cells
[152]. Therefore, preventive vaccination to avoid uncon-
trolled virus replication and successive “scaring” of the im-
mune system could decrease the incidence of EBV-associated
malignancies. In particular, vaccine strategies for the im-
munotherapy of EBV-related tumors should seek to elicit or
boost speciﬁc cellular immune response against EBV anti-
gens expressed in these malignancies. Individuals likely to
beneﬁt from this approach are EBV-seronegative patients
prior to solid organs transplant or patients with EBV-
associated malignancies with a low tumor burden or in
remission. However, vaccine strategies are unlikely to be the
optimalmethodtoenhanceEBV-speciﬁcT-cellresponsesfor
patients who are immunocompromised, due to immuno-
suppressive therapies after transplantation or as a result of
disease-related immune alterations such as in HL. In these
cases, the adoptive immunotherapy with ex vivo activated
EBV-speciﬁc CTL (EBV-CTLs) seems to be more promising,
also because it allows genetic modiﬁcations of T cells able to
enhance their function.
4.2. EBV-Speciﬁc Adoptive Immunotherapy (ACT) in PTLDs.
EBV infection poses a signiﬁcant problem in transplant
patients who are iatrogenically immunosuppressed in order
to prevent chronic organ rejection. Risk factors for the
development of PTLD include EBV-seronegativity in the
transplant recipient, the type of organ transplanted (highest
in lung and heart and lowest in liver and kidney), and the
level and type of immune suppression [27]. PTLD emerges
as either of recipient or donor origin, depending on the
type of transplant. For example, bone marrow transplant
(BMT) patients develop PTLD of donor origin, as EBV-
infected B cells derived from the donor marrow proliferate
uncontrollably into lymphoma. Conversely, solid organ
transplant patients develop PTLD of recipient origin, as EBV
released from the transplanted organ infects the recipient’s B
cells [28]. On these grounds, initial studies investigated the
potential of EBV-speciﬁc CTLs to treat PTLD in BMT pa-
tients, as CTLs could be easily generated from EBV-
seropositive, immunocompetent donors. Pioneering studies
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adoptive transfer of EBV-CTLs grown from donor periph-
eral blood mononuclear cells. The method developed to
stimulate and expand large numbers of EBV-CTLs utilized
donor’s autologous EBV-immortalized lymphoblastoid B-
cell lines (LCLs), which were cocultured with donor PBMCs
in the presence of interleukin-2 (IL-2). Similar to PTLD
tumor cells, LCLs also have a latency III phenotype and
can activate polyclonal EBV-speciﬁc CTLs with a broad
reactivity to a range of EBNA- and LMPs-derived epitopes.
The resulting EBV-CTLs used in these studies killed donor
LCLs in vitro, did not compromise allograft function, and
most importantly, eradicated tumors [154].
4.3. EBV-Speciﬁc ACT in NPC and HL. Clinical evidence
accumulated so far indicates that ACT with EBV-CTLs is safe
and well tolerated. Even if this approach results particularly
eﬀective in the case of most immunogenic tumors, as previ-
ouslydescribedinPTLDs[155],inLatencyIIEBV-associated
malignancies, the more restricted pattern of viral latent anti-
gen expression, together with local immune suppression and
immuneevasionoftumorcells,stronglylimitthetherapeutic
potential of EBV-CTLs obtained by conventional protocols.
In particular, the infusion of EBV-targeted autologous CTLs
was shown to enhance speciﬁc immune responses and to
induce objective clinical responses only in a proportion of
NPC and HL cases [156, 157], probably due to the weak
immunogenicity of LMPs [67, 158]. On these grounds,
recombinant viruses encoding for EBNA1, LMP1, and LMP2
antigens have been used to improve protocols for the in vitro
expansion of EBV-CTLs and in vivo data showed that they
were also able to protect against LMP-positive tumor growth
in mice [159–161]. Accordingly, interesting results were
recently obtained by Bollard and colleagues on 10 selected
HL patients, by the induction and in vivo persistence of
LMP2-speciﬁc CTLs, using genetically modiﬁed APCs [162].
The authorsshowed that 9 of10 patients treatedin remission
of a high-risk disease remained in remission, and 5 of 6
patients with active relapsed disease had a tumor response,
which was complete in 4 and sustained for more than
9 months [162]. Furthermore, these EBV antigen-speciﬁc
eﬀector lines are being tested, with promising results, also
in NPC patients [158, 163–165]. Unfortunately, although
LMP2-speciﬁcCTLscouldbeexpandedexvivoafterpeptide-
pulsed DC injection in NPC patients [156], these responses
were usually weak or transient. Learning from these trials
and as a result of a better understanding of the crucial role
for CD4+ T cells in assisting CD8+ T-cell immunity, more
recent stimulation protocols aim to incorporate both CD4+
and CD8+ T cell antigens [65, 158]. Indeed, in addition to
CD4+ T-cellhelpforCD8+ T-cellresponses,CD4+ Tcellscan
also target and kill EBV-transformed B cells directly [166].
Finally, considering that NPC and HL malignant cells have
functional antigen-processing machinery and express HLA
and costimulatory molecules [72, 167], the demonstration
that other viral latent proteins expressed by these neoplastic
cells may serve as tumor-associated antigens could provide
the rational background to improve the clinical eﬃcacy
of ACT protocols in this setting. Particularly promising in
this respect is the demonstration that the oncogenic EBV-
encoded BARF1 protein, expressed by most NPCs, is immu-
nogenic and thus may be exploited as additional target of
innovative ACT protocols [168]. Therefore, ACT with EBV-
CTLs has proven to be an eﬀective strategy in the post-
transplant setting, being able to reconstitute EBV-speciﬁc
immunity [23], to prevent the development of PTLD [28]
and treat patients with established PTLD. For other EBV-
associated malignancies, the use of EBV-CTL has proven less
eﬃcacious; however, the results obtained so far are suﬃ-
ciently encouraging to justify continued active exploration of
this approach. Novel approaches are being developed to
enhance the potency of EBV-speciﬁc immunotherapy by tar-
geting CTL to subdominant EBV proteins and by genetically
modifyingtheseeﬀectorcellstorenderthemresistantagainst
inhibitory cytokines or immunosuppressive therapies [169,
170]. Notably, such strategies could have relevant implica-
tions for the ACT of a broader spectrum of human cancers
with deﬁned tumor antigens. All these approaches open
promising avenues to enhance or prime protective EBV-
speciﬁc immune responses, which have been suppressed by
the tumor cells itself or by their microenvironment, and
whose absence might predispose for the development of
EBV-associated malignancies.
5. InnateImmunity-BasedTherapies for
EBV-Driven Tumors
Traditional approaches to exploit innate immunity for
cancerimmunotherapyincludetheactivationofendogenous
eﬀectors (mainly NK cells) with systemic administration
of cytokines (IL-2, etc.) and the adoptive infusion of ex
vivo expanded NK or lymphokine-activated killer (LAK)
cells. The potent immunostimulatory eﬀect of systemic IL-
2 in advanced cancer patients has been originally demon-
strated by the seminal work of Rosenberg and collaborators
[171, 172]. Since then, several clinical trials based on IL-2
administration have been carried out in diﬀerent cohorts
of cancer patients, mainly including melanoma, renal cell
carcinoma, neuroblastoma, breast cancer, and several hema-
tologic malignancies [173–177]. Notably, low-dose IL-2
was successfully used for the treatment or prevention of
lymphomas associated with human immunodeﬁciency virus
(HIV) infection, which include a signiﬁcant proportion of
EBV+ cases [178]. In these lymphoma patients, IL-2 treat-
ment results in increased absolute numbers of NK cells, with
no signiﬁcant change in T-cell subsets or plasma HIV RNA
levels [179]. Clinical experience however indicate that IL-
2 can cause systemic toxicities, a limitation that could be
overcome by the use of IL-15, a less toxic cytokine that plays
essential roles in NK cell development, homeostasis, and
survival [180]. Moreover, availability of clinical-grade IL-15
also opens new avenues to improve the generation of NK
cells for adoptive cancer immunotherapy [181]. It should be
considered, however, that the ability of NK cells to recognize
and kill tumor cells may be attenuated with progression
of the disease through several mechanisms, including the
upregulation of negative regulators of immune responses,12 Clinical and Developmental Immunology
such as the ligand of Programmed Death-1 (PD-1) (PD-L1)
[182, 183]. While the constitutive or inducible expression of
PD-1 has been characterized in B, T, and dendritic cells, little
isknownregardingPD-1expressiononNKcells.Recentdata
indicate that the PD-1/PD-L1 signaling axis mediates NK
cell activation and cytotoxicity against multiple myeloma. In
particular, the use of a monoclonal antibody targeting the
PD-1 molecule expressed by NK cells was shown to enhance
NK cell cytotoxicity against tumor cells [184], providing the
rationale to include these drugs in new therapeutic regimens
for multiple myeloma. Several investigators have reported
high levels of PD-1 expression on EBV-speciﬁc CD8+ Tc e l l s
during acute or chronic infection [185, 186], but data on
the expression of this inhibitory molecule on NK cells from
patients with EBV-driven tumors are lacking.
Several lines of evidence indicate that innate immunity
may usefully complement the antitumor immune responses
induced by ACT. After total body irradiation, in fact, the
damage of mucosal barriers results in the spreading of bacte-
rial products, TLR agonists and proinﬂammatory cytokines
that promote the activation of APC [187]. Moreover, it has
been also demonstrated that TLR agonists may function as
promising adjuvants for ACT protocols [188]. In a mouse
melanomamodel, TLRagonistswereshowntoenhanceACT
in two functional phases: ﬁrst, by favouring the interactions
between activated host DCs and adoptively transferred
CTLs; second, by enhancing the antitumor activity of T
lymphocytes through IFNγ-dependent mechanisms [188].
Thiscertainlyconstitutesapromisingapproachthatdeserves
to be validated in humans. Besides working in combination
with adoptively infused T cells, innate immunity eﬀectors
may be also used as a direct cell-based immunotherapy for
human cancers, particularly those associated with oncogenic
viruses. NK cells, in fact, can be an attractive alternative
to ACT because they preferentially target MHC-class-I-
deﬁcient tumor cells. Moreover, NK cells can inﬂuence
other immune cells by producing cytokines able to pro-
mote DC diﬀerentiation, antigen presentation, and CTL
activity. Importantly, NK cells can eliminate immature,
tolerizing DCs, allowing thus an improved presentation of
tumor antigens to T cells. Pioneering studies by Velardi
and coworkers demonstrated that alloreactive NK cells, if
unrestrained by inhibitory signals from the recipient HLA
ligands,areeﬀectiveinprotectingagainstdiseaserelapseafter
hematopoietic stem cell transplantation [189]. Although
available evidence indicates that alloreactive NK cells are
eﬀective in the setting of hematologic malignancies, this
strategy remains to be extensively tested in patients with
solid tumors, including EBV-associated carcinomas. Several
methods are now available for ex vivo expansion of NK
cells [190] and the critical issues related to the development
of successful NK cell-based adoptive immunotherapy have
been recently reviewed [191]. In the setting of EBV-driven
tumors, exploitation of NK cells for therapeutic purposes
seems particularly attractive, considering the pivotal role of
these eﬀectors in controlling EBV-infected cells. Moreover,
IL-2-activated peripheral blood NK cells were shown to
restrict EBV-induced B-cell transformation in vitro [86, 87]
and activated NK cells acquire the ability to kill lytically EBV
replicating B cells [192]. This latter eﬀect was associated with
downregulationofHLAclassImoleculesthatbindtoNKcell
inhibitory receptors, whereas activating receptors remained
upregulated [192]. In this respect EBV diﬀers from human
cytomegalovirus, which has evolved a complex and highly
eﬀective strategy for NK cell evasion. On these grounds,
the current therapeutic approaches for EBV-related tumors
based on the induction of EBV lytic replication would cer-
tainly beneﬁt from a retained or even enhanced functionality
of NK cells. It is worth considering in this respect that
there is increasing interest in pharmacologic activation of
lytic viral expression in EBV-driven malignancies [193].
Several drugs are able to trigger EBV lytic cycle, includ-
ing gemcitabine, doxorubicin, various histone deacetylase
inhibitors (trichostatin A, sodium butyrate, valproic acid,
suberoylanilide hydroxamic acid), and bortezomib [193–
195]. Particularly promising is the combination of EBV lytic
cycle inducers with antiviral agents, as shown by the results
of a phase I/II trial of arginine butyrate and gancyclovir in
refractory EBV-associated lymphoid malignancies [196].
Cellular microRNAs (miRNAs) are emerging as new
promising therapeutic targets for human cancers by virtue of
their role in regulating numerous processes, also including
immune responses [197]. In particular, recent advances have
suggested new modalities to improve T-cell-based cancer
immunotherapy by engineering distinct miRNAs. Targeting
miR-17-92 is a promising approach considering that its
downregulationinTcellsfromtumor-bearingmiceandcan-
cer patients is associated with a Th2 skewing and impaired
antitumor responses [198]. Forced expression of miR-17-92
in T lymphocytes could therefore confer resistance to tumor-
derived immunosuppressive factors, such as TGF-β and
improve Th1 reactivity. Similarly, over-expression of miR-
155 promotes Th1 diﬀerentiation of CD4+ T cells through
the regulation of IFN-γRα chain [199]. Moreover, it has been
shown that miR-181 regulates the strength and sensitivity
of TCR-mediated T-cell activation by acting through mod-
ulation of multiple phosphatases [200]. It would be relevant
to assess whether ectopic expression of miR-181 would lead
to enhanced TCR signaling and a reduced T-cell activation
threshold in T cells recognizing weak tumor-associated
antigens. While the expression and importance of miRNAs
inTandBlymphocyteshavebeenestablished,littleisknown
about the role of miRNAs in NK cells. The recent character-
ization of NK cell miRNA transcriptome by next-generation
sequencing will provide a valuable framework to identify
critical miRNAs that can be targeted to improve NK cell
function in cancer patients [201]. Considering that NK cells
alsoshareanmiRNAproﬁlewitheﬀectorandmemoryCD8+
T cells [202], the possibility to target miRNAs regulating
pathways common to innate and adaptive immunity appears
particularly attractive. miRNAs expressed by EBV-infected
tumor cells may be also relevant for therapeutic purposes.
In fact, cellular miRNAs 200b and 429 are key regulators of
the switch between latent and lytic EBV infection, thus con-
stituting attractive targets for the development of new lytic
induction therapeutics [203].Clinical and Developmental Immunology 13
6. Concluding Remarks
Innate and adaptive immunity are both crucial for an eﬀec-
tivecontrolofanoncogenicvirussuchasEBV.Thesuccessof
adoptive T-cell therapy for EBV-driven PTLDs is stimulating
the development of new immunotherapeutic strategies for
EBV-associatedtumors.Consideringthatadaptiveimmunity
has coevolved with innate immunity to warrant protection
from infections, innovative immunotherapeutic approaches
should take into account both compartments to be more
clinically eﬀective. Evidence accumulated so far indicates
that innate immunity eﬀectors, particularly NK cells, can be
exploited with therapeutic purposes and new targets have
been recently identiﬁed. Nevertheless, only few clinical stud-
ies are investigating the possible eﬃcacy of treatments ex-
ploitingbothinnateandadaptiveantitumorimmunity.EBV-
driven tumors constitute a particularly suitable setting to
address this clinically relevant issue.
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